Noncoding RNAs as sensors of tumor microenvironmental stress

Yue Lv1†, Yinghao Lv1†, Zhen Wang1,2†, Kefei Yuan1,2* and Yong Zeng1,2*

Abstract
The tumor microenvironment (TME) has been demonstrated to modulate the biological behavior of tumors intensively. Multiple stress conditions are widely observed in the TME of many cancer types, such as hypoxia, inflammation, and nutrient deprivation. Recently, accumulating evidence demonstrates that the expression levels of noncoding RNAs (ncRNAs) are dramatically altered by TME stress, and the dysregulated ncRNAs can in turn regulate tumor cell proliferation, metastasis, and drug resistance. In this review, we elaborate on the signal transduction pathways or epigenetic pathways by which hypoxia-inducible factors (HIFs), inflammatory factors, and nutrient deprivation in TME regulate ncRNAs, and highlight the pivotal roles of TME stress-related ncRNAs in tumors. This helps to clarify the molecular regulatory networks between TME and ncRNAs, which may provide potential targets for cancer therapy.

Keywords: LncRNAs, CircRNAs, Hypoxia, Inflammation, Nutrient deprivation

Background
Until the 1980s, cancer research was dominated by a tumor-centric view assuming that mutations in oncogenes and tumor suppressor genes were responsible for the whole processes of cancer development and progression before. However, with the continuous deepening of the research, scientists have shifted their focus from cancer cells to their surrounding microenvironment [1]. The tumor microenvironment (TME) mainly consists of diverse cellular and non-cellular constituents. The cellular constituents comprise endothelial cells, cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), lymphocytes, antigen-presenting cells, pericytes, and neoplastic cells. Non-cellular constituents include extracellular matrix as well as secreted products of TME cells, such as pro-inflammatory cytokines, chemokines, growth factors, and metabolites [2]. Undergoing a series of dynamic alterations, the physical and chemical characteristics of TME become different from those of normal tissues. Most strikingly, various stress conditions emerge in TME, such as low oxygen tension, acidosis, inflammation, nutrient deprivation, oxidative stress, and endoplasmic reticulum stress. Stress conditions of TME exhibit strong correlations with cancer malignancy by playing critical roles in tumor growth, metastasis, and therapy resistance [2–6].

Large-scale genomic sequencing revealed that less than 2% of human genome transcripts encode proteins, whereas the vast majority can be transcribed into different classes of noncoding RNAs. Noncoding RNAs (ncRNAs) are defined as transcripts with minimal or no protein-coding capacity. NcRNAs can be roughly classified into two major categories based on their molecular length, including small ncRNAs (sncRNAs) (< 200nt in length) and long ncRNAs (LncRNAs) (> 200 nt in length). The sncRNAs consist of microRNAs (miRNAs), small interfering RNAs (siRNAs), small nucleolar RNAs (snoRNAs), small nuclear RNAs (snRNAs); transfer RNA-derived small RNAs (tsRNAs),...
PIWI-interacting RNAs (piRNAs), etc. Notably, lncRNAs constitute a large portion of noncoding transcripts of the human genome [7, 8]. lncRNAs serve as functional regulatory molecules that mediate gene transcription, chromatin remodeling, post-transcriptional modification, and signal transduction. Numerous studies have identified lncRNAs as either oncogenic drivers or tumor suppressors that are implicated in diverse cellular processes, including tumor cell proliferation, metabolism, apoptosis, metastasis, immune evasion, and resistance to therapies, etc. [7, 9]. With technology advances like high-throughput transcriptome sequencing and RNA microarray, an impressive number of lncRNAs were identified to be differentially expressed in cancer in response to different TME stresses [10–14]. Consequently, elucidation of the complicated interactions between TME stress and lncRNAs in the process of tumorigenesis and development has become a research hotspot.

In this review, we systematically summarize the diverse molecular mechanisms by which various TME stresses dysregulate ncRNA expression, and discuss how these stress-responsive ncRNAs regulate tumorigenesis and cancer progression.

### NcRNAs regulated by hypoxia

Intratumoral hypoxia (0.5–2% oxygen), an important hallmark in TME, originates from a mismatch between insufficient oxygen supply caused by ineffective vasculature and elevated metabolic demands from rapid cancer cell proliferation. Cancer cells sense a decline in oxygen level and elicit multiple genomic alterations and adaptive cellular responses, enabling themselves to adapt to low oxygen availability, which further promotes cancer initiation and progression [4]. Of note, emerging evidence has indicated that a vast variety of ncRNAs (e.g., miRNA, lncRNA, circRNA, and piRNA) are differentially expressed in response to hypoxia and exert crucial roles in cancer development [10, 15]. Nevertheless, the diverse mechanisms whereby hypoxia modulates ncRNAs have rarely been systematically discussed. Hypoxia-inducible factors (HIFs), as central regulators for detecting and adapting to fluctuations in oxygen level, are known to orchestrate hypoxia-responsive gene expression in cancer [16]. Herein, based on the relevance to transcription factor HIFs, we simply categorize the regulatory mechanisms of ncRNAs upon hypoxia into regulations with the involvement of HIFs (HIFs-dependent), or regulations without the involvement of HIFs (HIFs-independent). The detailed modes of regulation and functions of these hypoxia-responsive ncRNAs in cancer are summarized in the section below (Table 1, Fig. 1).

### HIFs-dependent manner

ncRNAs can be either directly or indirectly regulated by HIFs during hypoxic stress. To be specific, ncRNAs can be directly transcribed by HIFs, on the other hand, ncRNAs can act as downstream effectors that are indirectly influenced by HIFs via other intermediate mediators. These will be further explained in the following part.

### Direct regulation by HIFs

Hypoxia has been well-established to modulate the expression of a myriad of ncRNAs, while the majority of them are direct transcriptional targets of HIFs [16]. The HIF family is a set of heterodimeric transcription factors composed of HIF-1α, HIF-2α, or HIF-3α and a constitutively expressed HIF-1β subunit. Upon hypoxia, oxygen depletion blocks the hydroxylation and subsequent degradation of HIF-1α, thus allowing HIF-1α to translocate into the nucleus where it dimerizes with HIF-1β. This complex then binds to hypoxia response elements (HREs) in the promoter regions of target genes to regulate ncRNA transcription [4, 50]. To date, hypoxia-responsive ncRNAs that are transcribed by HIF-1α have been largely identified. These ncRNAs are validated to contain HREs in their promoter regions by bioinformatics analysis or experiments such as chromatin immunoprecipitation (ChIP), luciferase reporter assays, or electrophoretic mobility shift assay (EMSA).

And these ncRNAs participate in cancer cell proliferation, metabolic reprogramming, apoptosis, metastasis, and therapy resistance in multiple cancer types [10]. Of the substantial miRNAs that are directly regulated by HIF-1α during oxygen deprivation, miR-210 is one of the most well-known and robustly upregulated miRNAs. MiR-210 overexpression has been detected in a variety of solid tumors, and a wide spectrum of its target genes have been identified, which are implicated in many stages of tumorigenesis [17]. Recently, a wealth of evidence has unraveled various lncRNAs and circRNAs that are transcriptionally regulated by hypoxia/HIF-1α signaling. For instance, lncRNA H19, MALAT1, NEAT1, and HOTAIR are frequently dysregulated upon hypoxic stress and play pleiotropic roles in many solid tumors [20–22, 25, 26, 28, 29]. Besides, the induction of circDENND4C and circWSB1 upon hypoxia are also attributed to the binding of HIF-1α to their promoters. Enhanced expression of circDENND4C facilitates glycolysis, migration, and invasion by sponging miR-200b and miR-200c or through the miR-760/GLUT1 axis in breast cancer or in colorectal cancer cells, respectively [31–33]. Overexpressed circWSB1 promotes breast cancer progression via destabilizing p53 by interacting with USP10 [34]. In addition, it is worth noting that a majority
| NcRNAs               | Expression upon hypoxia | Regulatory mechanisms                                                                 | Functions                                           | Cancer types                          | References            |
|---------------------|-------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------|---------------------------------------|-----------------------|
| miRNA-210           | Up-regulated            | HIF-1α/HIF-2α/p53/NF-κB/Oct-4/PPARγ-dependent transcriptional regulation; epigenetic modification | Promote multiple aspects of tumor growth             | Multiple cancer types                | [17–19]              |
| IncRNA H19          | Up-regulated            | HIF-1α dependent transcriptional regulation affected by SP1 or PTEN                  | Promote proliferation, migration, invasion, angiogenesis | Multiple cancer types                | [20, 21]              |
| IncRNA MALAT1       | Up-regulated            | HIF-1α dependent transcriptional regulation, HIF-1α dependent histone demethylation, chromatin looping | Promote cellular proliferation rates, EMT, and metastasis | Multiple cancer types                | [22–24]              |
| IncRNA NEAT1        | Up-regulated            | HIF-1α/HIF-2α dependent transcriptional regulation                                   | Induce paraspeckle formation and accelerate cell proliferation | Multiple cancer types                | [25–27]              |
| IncRNA HOTAIR       | Up-regulated            | HIF-1α dependent transcriptional regulation                                          | Enhance cancer cell proliferation, migration, and invasion | Multiple cancer types                | [28–30]              |
| circRNA DENND4C      | Up-regulated            | HIF-1α dependent transcriptional regulation affected by coactivator CBP/p300 or MLL1 | Promote proliferation, migration, and glycolysis     | Breast cancer, colorectal cancer      | [31–33]              |
| circRNA WSB1         | Up-regulated            | HIF-1α dependent transcriptional regulation                                           | Promote proliferation                               | Breast cancer                        | [34]                  |
| IncRNA HAS2-AS1      | Up-regulated            | HIF-1α/NF-κB dependent transcriptional regulation                                   | Promote EMT and invasiveness                         | Oral squamous cell carcinoma         | [35]                  |
| lincRNA-p21          | Up-regulated            | HIF-1α dependent transcriptional regulation                                           | Modulate the Warburg effect                          | Cervical cancer                      | [36]                  |
| circRNA MAT2B        | Up-regulated            | HIF-1α dependent transcriptional regulation                                           | Facilitate glycolysis and proliferation               | Gastric cancer                       | [37]                  |
| IncRNA PVT1          | Up-regulated            | HIF-1α dependent transcriptional regulation                                           | Promote glycolysis and proliferation                 | Pancreatic cancer                    | [38]                  |
| circRNA ZNF91        | Up-regulated            | HIF-1α dependent transcriptional regulation                                           | Enhance glycolysis and chemoresistance               | Pancreatic cancer                    | [39]                  |
| IncRNA BCRT1         | Up-regulated            | HIF-1α dependent transcriptional regulation                                           | Promote proliferation and metastasis                 | Breast cancer                        | [40]                  |
| IncRNA RAB1B-AS1     | Up-regulated            | HIF-2α dependent transcriptional regulation                                           | Promote angiogenesis and metastasis                  | Breast cancer                        | [41]                  |
| IncRNA SARCC         | Down-regulated          | HIF-2α dependent transcriptional regulation                                           | Suppress cell proliferation                          | Renal cell carcinoma                 | [42]                  |
| IncRNA-LET           | Down-regulated          | HIF-1α dependent histone deacetylation                                              | Promote metastasis                                   | Hepatocellular carcinomas, colorectal cancer, squamous-cell lung carcinoma | [43]                  |
| IncRNA CF129         | Down-regulated          | HIF-1α dependent histone deacetylation                                              | Inhibit proliferation and invasion                   | Pancreatic cancer                    | [44]                  |
| IncRNA WT1-AS        | Up-regulated            | HIF-1α dependent DNA demethylation                                                  | Regulate developmental gene                          | Myeloid Leukemia                     | [45]                  |
| miRNA-424            | Up-regulated            | PU.1 dependent transcriptional regulation                                            | Promote angiogenesis                                 | Ovarian cancer                       | [46]                  |
| IncRNA LASTR         | Up-regulated            | c-JUN dependent transcriptional regulation                                           | Foster cancer cell fitness                           | Triple-negative breast cancer        | [47]                  |
| miRNA-148a           | Down-regulated          | Hypermethylation of CpG islands                                                      | Promote metastasis                                   | Multiple cancer types                | [48]                  |
| miRNA-34b/c          | Down-regulated          | Hypermethylation of CpG islands                                                      | Promote metastasis                                   | Multiple cancer types                | [48, 49]              |
of these hypoxia-responsive ncRNAs are discovered via high-throughput RNA-seq or RNA-microarray. As an example, Zhu et al. performed a lncRNA microarray (GEO accession number: GSE84807) to analyze the aberrant lncRNA expression profiles in oral squamous cell carcinoma (OSCC) cell lines cultured under normoxia and hypoxia, screening top 10 lncRNAs that were significantly upregulated (Additional file 1: Figure S1a), among which lncRNA HAS2-AS1 was the only lncRNA directly targeted by HIF-1α and was associated with lymph node metastasis in patients with OSCC, thus being selected for further investigation. Functionally, HAS2-AS1 mediated the hypoxia-regulated EMT process via increasing HAS2 and HA production, conferring a migratory and invasive phenotype to OSCC cells [35]. Most importantly, many of these hypoxia/HIF-1α-regulated ncRNAs can conversely modulate HIF-1α expression, forming a positive/negative feedback loop as a response to hypoxic stress [26]. One such example is lincRNA-p21, which is transcriptionally induced by HIF-1α under hypoxia, can in turn interrupt the HIF-1α-VHL interaction, thereafter stabilizing HIF-1α and upregulating genes involved in glycolysis in colorectal cancer cells [36]. Likewise, in the pathogenesis of gastric cancer, the circMAT2B/miR-515-5p/HIF-1α feedback circuit reinforces HIF-1α signaling, which then amplifies the oncogenic effect of circMAT2B, eventually
facilitating glycolysis [37]. Similar feedback loops also exist in the hypoxic regulation of MALAT1 [22], HOTAIR [30], lncRNA PVT1 [38], and circZNF91 [39]. Intriguingly, instead of having an impact on neoplastic cells, certain hypoxia-sensitive ncRNAs can also orchestrate the cellular behavior of various stromal cells within TME, therefore contributing to tumor progression. One such example is lncRNA BCRT1, whose expression is strongly induced in breast cancer cells as a response to hypoxia through HIF-1α-dependent transcriptional regulation. BCRT1 can be transferred from breast cancer cells to macrophages via exosomes, which promotes M2 phenotype polarization and enhances tumor-promoting properties of macrophages [40].

Similar to HIF-1α, HIF-2α is also capable of mediating the hypoxic induction of ncRNAs at transcriptional level by forming a transcription complex with HIF-1β. Importantly, it is reported that HIF-1α serves as central transcriptional mediators in acute hypoxia, while HIF-2α mainly functions in chronic hypoxia [51]. HIF-3α inhibits HIF-dependent regulation of target genes via competition with HIF-1α and HIF-2α [52]. Of note, HIF-1α and HIF-2α orchestrate the expression of both overlapping and unique sets of ncRNAs. However, compared to HIF-1α, ncRNAs that are regulated by HIF-2α remain less identified. In low oxygen tension, lncRNA RAB11B-AS1 induction is only specifically driven by HIF-2α. Silencing of HIF-2α, instead of HIF-1α, markedly attenuates the hypoxic elevation of RAB11B-AS1 expression in breast cancer cells. RAB11B-AS1 then promotes hypoxia-mediated angiogenesis and metastasis in breast cancer [41]. In contrast, miR-210, lncRNA NEAT1, and MALAT1 are induced at transcriptional level under hypoxic conditions in both HIF-1α/HIF-2α-dependent fashion. Although both HIF isoforms bind to the NEAT1 and MALAT1 locus, these two lncRNAs are regulated predominantly by HIF-2α rather than HIF-1α, indicating a post-binding mechanism of transcriptional selectivity [26, 53, 54]. Aside from transcriptional activation, it is reported that HIF-2α can transcriptionally repress lncRNA SARCC expression in renal cell carcinoma (RCC) through binding to HREs located within SARCC promoter. LncRNA SARCC functions as a key modulator that connects hypoxia/HIF-2α signaling to the AR/HIF-2α/C-MYC axis, forming a negative feedback loop and hence suppressing RCC cell proliferation [42]. Taken together, we conclude that hypoxia-responsive ncRNAs are directly regulated by HIF-1α and/or HIF-2α.

It is worth mentioning that the interactions between HIF-1α and other transcription factors or coactivators also influence ncRNA expression upon hypoxia. As an example, it is reported that lncRNA H19 elevation upon hypoxic stress is governed by HIF-1α and p53 status. Under low oxygen concentration, H19 is dramatically upregulated by HIF-1α in p53 null hepatocellular carcinoma (HCC) cells, whereas it is not affected in wild-type p53 HCC cells, suggesting that p53 interferes with the transcriptional activity of HIF-1α [55]. Alternatively, in glioblastoma (GBM), specific protein 1 (SP1) plays a crucial intermediary role in HIF-1α-mediated H19 expression via binding GC-boxes in the H19 promoter. Likewise, phosphatase and tensin homolog (PTEN) is shown to attenuate the stability of HIF-1α thereby repressing hypoxia-driven transcriptional induction of H19 in multiple GBM cell lines [20]. Similarly, transcription coactivators MLL1 and CBP/p300 are recruited to the lncRNA HOTAIR promoter region, cooperating with HIF-1α to stimulate HOTAIR expression and promote tumorigenesis [29]. Collectively, these findings indicate that HIFs-dependent direct transcriptional regulation of ncRNAs in response to hypoxia is affected by the involvement of other critical factors, however, the exact mechanisms of their actions remain to be clarified.

**Indirect regulation by HIFs**

Besides direct transcriptional regulation, HIFs have also been reported to modulate the expression of ncRNAs via indirect manners involving the participation of other intermediate factors. Mounting evidence has illustrated that hypoxia-induced HIFs influence the expression or activity of many epigenetic regulators to indirectly orchestrate epigenetic chromatin modification and subsequent gene expression [16]. For instance, it has been shown that hypoxia can alter the histone deacetylases (HDACs) levels in a HIFs-dependent manner [16]. Recent studies have uncovered the role of the HIF-1α/HDACs complex in ncRNA regulation. Yang and colleagues demonstrated that lncRNA-LET downregulation in response to hypoxia was mediated by HIF-1α-induced expression of HDAC3, a downstream effector of HIF-1α. Elevation of HDAC3 blocked lncRNA-LET transcription via decreasing the level of histone H3 and H4 acetylation-mediated modulation in the lncRNA-LET promoter. Downregulation of lncRNA-LET further contributed to hypoxia-induced HCC metastasis through stabilization of NF90 protein. And the HIF-1α/HDAC3/lncRNA-LET/NF90 axis could establish a positive feedback circuit that augmented the HIF-1α response under hypoxic circumstances [43]. Similarly, HIF-1α halts the lncRNA CF129 transcription by recruiting HDAC1 to the promoter area of lncRNA CF129 under low oxygen tension. Downregulated CF129 potentiates the proliferation and invasion of pancreatic cancer cells by overexpressing FOXC2 in a p53-dependent manner. As a transcription factor, FOXC2 can reciprocally upregulate HIF-1α at transcription level, forming a lncRNA-involved regulatory feedback loop.
that mediates tumor progression during hypoxic stress [44]. Particularly, several HDACs were also reported to reciprocally enhance the stability and accumulation of HIFs, thus further accelerating the modulation of ncRNAs [16].

Apart from HDACs, several histone lysine demethylases (KDMs) are also known to be induced by hypoxia in a HIF-1α-dependent manner, which then regulate the expression of ncRNAs. For example, Ikeda et al. observed a HIF-1α-dependent induction of KDM3A under chronic hypoxia in multiple myeloma cell lines. KDM3A subsequently activates lncRNA MALAT1 transcription via histone demethylation at its promoter region. The HIF-1α-KDM3A-MALAT1 axis contributes to acquisition of the antiapoptotic phenotype via upregulation of glycolysis-promoting genes [23].

In addition, the study of McCarty et al. revealed another model for hypoxia-mediated epigenetic regulation of ncRNA expression: hypoxia elicits both a decrease in DNA methyltransferase 1 (DNMT1) expression and activity, while an increase in ten-eleven-translocation 2 (TET2) and ten-eleven-translocation 3 (TET3) expression and activity, resulting in demethylation of a CpG island in Intron 1 of WT1 gene, which allows the upregulation of lncRNA WT1-AS that correlates with increased mRNA WT1 expression. Notably, the hypoxic induction of WT1-AS could be abolished by HIF-1α knockdown, suggesting the critical involvement of HIF-1α [45]. Overall, these examples indicate that HIFs can indirectly regulate ncRNA expression via various forms of epigenetic modulation.

**HIFs-independent manner**

Although it is well-appreciated that HIFs act as a central hub in coordinating hypoxia-responsive ncRNA expression under exposure to low oxygen levels, several studies demonstrated that silencing HIF-1α and/or HIF-2α do not block or only partially block hypoxic induction of several ncRNAs [24, 56, 57], indicating the existence of HIFs-independent regulatory pathways of ncRNAs under hypoxia. These HIFs-independent mechanisms mainly comprise transcriptional and post-transcriptional regulation.

**Transcriptional regulation**

Increasing evidence implicates that hypoxia not just stimulates HIFs expression, but also a range of other transcription factors. Transcription factors including p53, NF-κB, CREB, SP-1, ATF4, STAT3, c-Myc, c-JUN, etc., were shown sensitive to oxygen levels and drive transcriptional response to varying degrees under hypoxia [10, 58, 59], suggesting that these transcription factors may also contribute to the transcription of ncRNAs under oxygen deprivation. Many studies have shown that hypoxia can regulate miRNA expression via various kinds of transcription factors. For example, the well-studied miR-210 contains multiple conserved transcription factor recognition sites in its genomic region, including p53, NF-κB, Oct-4, and PPARγ which are hypoxia-regulated genes [18, 19]. Besides, miR-424 is upregulated in hypoxic endothelial cells by transcription factor PU.1-dependent transactivation, thus promoting angiogenesis in ovarian cancer [46]. Zhu et al. reported that hypoxia facilitated the transcription of lncRNA HAS2-AS1 via transcription factor NF-κB. HAS2-AS1 mediated the hypoxia-induced invasive properties of OSCC cells via stabilizing HAS2 [35]. Another recent study validates that the expression of lncRNA LASTR is triggered by stress-activated JNK/c-JUN pathway under hypoxia through binding of the transcription factor c-JUN to LASTR transcription start site. In silico prediction and ENCODE ChIP-seq did not reveal any HREs located in the LASTR promoter. In this study, LASTR is selected as a representative lncRNA following RNA-seq (GEO accession number: GSE129344) and TCGA data analysis, showing robustly upregulated expression upon hypoxia (Additional file 1: Figure S1b) and close relevance to breast cancer malignancy. LASTR overexpression fosters cancer cell fitness by regulating the activity of the U4/U6 recycling factor SART3 [47]. These results confirmed that the transcription of ncRNAs can be modulated by other transcription factors other than HIFs in low oxygen tensions. Nevertheless, more transcription factors apart from c-JUN require to be identified.

Chromatin reprogramming, which is a well-established phenomenon during pathological conditions like cancer, also frequently emerges in hypoxic TME and regulates the transcription of a broad spectrum of genes in response to hypoxia [60, 61]. As an example, the hypoxia-induced hypermethylation of CpG islands leads to the transcriptional silencing of miR-148a and miR-34b/c, which promotes the metastatic capabilities of various cancers [48, 49]. Additionally, a recent research uncovers that hypoxia triggers cancer-cell-specific chromatin-chromatin interactions between enhancer-like cis-regulatory elements present at the lncRNA MALAT1 locus, which facilitates transcription of MALAT1 in breast cancer. Functionally, MALAT1 overexpression elevates the proliferation rate, EMT process, and metastatic potential of breast cancer cells. In this study, researchers indicate that hypoxia can stimulate MALAT1 expression in both HIFs-dependent and HIFs-independent manners, and they predict that numerous chromatin looping events remain to be uncovered which might influence hypoxia-responsive ncRNA expression [24].
Post-transcriptional regulation
NcRNA biogenesis is a complicated multistep process that integrates various enzymes and regulatory proteins to ensure an accurate maturation of ncRNAs, whereas, in multiple human malignancies, many components of the ncRNA biogenesis machinery could be deregulated, leading to aberrant ncRNA expression. For instance, it is well-established that miRNA processing undergoes dysregulation upon hypoxic stress, as a result of the significant downregulation of key proteins like DROSHA and DICER and many other miRNA processing subunits [62]. Besides, as one of the post-transcriptional gene regulatory mechanisms, alternative splicing (AS) has been proven to have an impact on the biogenesis and biological behavior of miRNAs, IncRNAs, and circRNAs [63, 64]. Importantly, it has been demonstrated that hypoxia could trigger abnormal AS events in cancer [58]. Nevertheless, the AS dysregulation of IncRNAs and circRNAs in low oxygen availability remains greatly unexplored with regard to their molecular mechanisms and biological functions in tumor pathogenesis. In addition, hypoxia can activate adenosine-to-inosine RNA sequence editing in cancer cells, which is also a post-transcriptional means of noncoding gene regulation [65, 66]. Furthermore, it was previously reported that under low oxygen tension, RNA-binding proteins (RBPs) and miRNAs could bind to mRNAs and impact mRNA turnover to modulate hypoxic gene expression profile [67]. Similarly, ncRNAs (e.g., IncRNAs, circRNAs) are recently shown to physically bind with RBPs and miRNAs, which can affect ncRNA biogenesis, stability, and function [68–70]. However, it remains unknown whether this post-transcriptional modification of ncRNAs can also be affected by hypoxia.

In conclusion, these studies provide further knowledge on the diverse mechanisms of hypoxia-triggered alterations of ncRNA expression, adding another layer of complexity in understanding how a hypoxic TME is implicated in cancer formation and progression.

NcRNAs regulated by inflammation
Chronic inflammation, as one of the defining hallmarks of cancer, is commonly observed in multiple human malignancies [71]. Considerable progress has been made in understanding the association between cellular/molecular events under inflammatory stimuli and tumor development. Under chronic inflammation in TME, stromal cells, infiltrating immune cells, and neoplastic cells produce a myriad of inflammatory factors that orchestrate an intricate inflammatory signaling network to modulate tumorigenesis and progression. These inflammatory factors include a variety of cytokines, chemokines, and growth factors [2, 72]. A growing body of evidence has revealed that inflammatory factors exert regulatory effects on ncRNAs via various pathways, such as Janus kinase-signaling transducer and activator of transcription (JAK/STAT) signaling pathway, nuclear factor-kB (NF-kB) signaling pathway, or chromatin remodeling, etc. Intriguingly, emerging evidence has indicated that the regulation of ncRNAs by inflammation in TME is not a one-way road. Many ncRNAs which are under regulation by inflammatory stimuli, can contribute to the production of a variety of inflammatory factors, which may in turn aggravate or repress the cancer-related inflammation. In the following context, we present an overview of the distinct mechanisms through which ncRNAs are induced by various inflammatory factors while highlighting how these inflammation-associated ncRNAs play pivotal roles in linking inflammation to malignant phenotype (Table 2, Fig. 2).

Cytokines
In inflammatory TME, cytokines like interleukins (ILs), tumor necrosis factors (TNFs), and interferons (IFNs) can be either autocrine, produced by neoplastic cells, or paracrine, released from adjacent stromal cells or immune cells [71]. These cytokines are demonstrated to drive aberrant expression of ncRNAs, which exert diverse functions in cellular processes during cancer initiation and malignant progression.

Interleukins
A variety of interleukins are abnormally produced in the presence of inflammatory stimuli. As a consequence, many inflammatory signaling pathways such as IL-6/JAK/STAT3 axis are frequently hyperactivated in multiple human cancers, executing pro-tumorigenic functions. The elevated levels of phosphorylated STAT3 are observed to translocate into the nucleus and initiate transcription of a vast array of ncRNAs [102]. To date, the IL-6/STAT3 axis has been well-documented to manipulate the expression of numerous miRNAs, including miR-21 [73], miR-17–92 [75], and miR-146b [76], and establish various regulatory feedback loops which further impact malignant progression. For example, IL-6/STAT3-induced miR-17–92 targets JAK/STAT3 pathway inhibitor SOCS3 and PIAS3, generating a positive feedback loop that amplifies IL-6/STAT3 signaling and contributes to cholangiocarcinoma cell proliferation and invasion [75]. Likewise, activation of IL-6/STAT3 axis induces IncRNA TCF7 expression in HCC cells. The binding of STAT3 to the promoter region of IncTCF7 upon IL-6 stimulation is confirmed by luciferase reporter assay and ChIP assay. In HCC, the aberrant IL-6/STAT3/IncTCF7 signaling axis boosts a malignant phenotype by accelerating the EMT process of HCC cells [77]. Besides, the IL-6/
STAT3 triggers transcription of lncRNA DANCR. Overexpression of DANCR then stabilizes PSMD10 which in reciprocal promotes IL-6 production, thus forming a feedback regulatory loop in reinforcing a pro-inflammatory TME and enhancing sorafenib resistance of HCC cells [78]. Another study reveals that under inflammatory stress, the hyperactivated IL-6/STAT3 axis in preleukemic Tet2-deficient hematopoietic stem and progenitor cells (HSPCs) results in elevated expression of lncRNA Morrbid via increased binding of STAT3 to the Morrbid promoter, which impedes apoptosis and enhances survival of Tet-KO HSPCs in response to acute inflammatory insults, ultimately promoting myeloid malignancies [79]. Similar to the IL-6/STAT3 pathway, IL-6 was shown to upregulate the expression of lncRNA ZEB2-AS1 through STAT1 pathway, which fostered the proliferation and migration of non-small cell lung cancer cells [80].

Table 2 Inflammation-regulated ncRNAs and their roles during cancer progression

| NcRNAs       | Expression in inflammation | Regulatory mechanisms                                      | Functions                                      | Cancer types                                    | References |
|--------------|----------------------------|-----------------------------------------------------------|------------------------------------------------|------------------------------------------------|-----------|
| miRNA-21     | Up-regulated               | IL-6/STAT3, IFN/JAK/STAT3 or IFN/NF-κB                  | Promote metastasis, modulate immune response  | Multiple cancer types                          | [73, 74]  |
| miRNA-17–92  | Up-regulated               | IL-6/STAT3                                               | Enhance proliferation, and invasiveness         | Cholangiocarcinoma                             | [75]      |
| miRNA-146b   | Up-regulated               | IL-6/STAT3                                               | Inhibit migration and invasion                 | Breast cancer                                  | [76]      |
| IncRNA TCF7  | Up-regulated               | IL-6/STAT3                                               | Promote EMT                                    | Hepatocellular carcinoma                      | [77]      |
| IncRNA DANCR | Up-regulated               | IL-6/STAT3                                               | Promote sorafenib resistance                   | Hepatocellular carcinoma                      | [78]      |
| IncRNA Morrbid| Up-regulated               | IL-6/STAT3                                               | Inhibit apoptosis                               | Acute myeloid leukemia                         | [79]      |
| IncRNA ZEB2-AS1 | Up-regulated              | IL-6/STAT1                                               | Enhance migration                              | Non-small cell lung cancer                    | [80]      |
| circRNA cGONBP2 | Up-regulated              | Circularization inhibition via DHX9                     | Promote cell growth and metastasis            | Intrahepatic cholangiocarcinoma                | [81]      |
| IncRNA MALAT1 | Up-regulated               | IL-6/STAT3, IL-8/STAT3 or CCL21                        | Promote cell proliferation and metastasis     | Multiple cancer types                          | [82–85]  |
| miRNA-181a   | Up-regulated               | IL-1β/NF-κB                                              | Promote cell proliferation                     | Colorectal cancer                              | [86]      |
| miRNA-425    | Up-regulated               | IL-1β/NF-κB                                              | Promote cell proliferation                     | Gastric cancer                                 | [87]      |
| IncRNA NKILA | Up-regulated               | TNF-α/NF-κB                                              | Suppress proliferation, metastasis            | Breast cancer; laryngeal cancer                | [88, 89]  |
| circRNA SND1 | Up-regulated               | TNF-α/NF-κB                                              | Promote migration and invasion                 | Cervical cancer                                | [90]      |
| miRNA-130a   | Up-regulated               | TNF-α/NF-κB                                              | Promote cell growth                            | Cervical cancer                                | [91]      |
| IncRNA AC007271.3 | Up-regulated        | TNF-α/NF-κB                                              | Promote proliferation, migration, invasion, and inhibit apoptosis | Oral squamous cell carcinoma | [92] |
| IncRNA HOTAIR | Up-regulated               | TNF-α/NF-κB or CCL18                                      | Promote proliferation, angiogenesis, drug resistance | Multiple cancer types                          | [93, 94]  |
| IncRNA LOC105374902 | Up-regulated         | TNF-α/STAT3                                              | Facilitate EMT process, migration, invasion   | Cervical cancer                                | [95]      |
| IncRNA IRF1-AS | Up-regulated              | IFN/JAK/STAT                                              | Inhibit proliferation and promote apoptosis    | Esophageal squamous cell carcinoma              | [96]      |
| IncRNA GASS  | Up-regulated               | IFN/JAK/STAT                                              | Inhibit proliferation, migration, and invasion | Esophageal squamous cell carcinoma              | [97]      |
| IncRNA LINC00092 | Up-regulated           | CXCL14                                                    | Promote glycolysis and metastasis             | Ovarian cancer                                 | [98]      |
| IncRNA XIST  | Up-regulated               | CXCL12/CXCR4                                              | Promote invasion and metastasis                | Colorectal cancer                              | [99]      |
| IncRNA LINC00319 | Up-regulated            | CCL18                                                     | Promote proliferation and metastasis          | Oral squamous cell carcinoma                   | [100]     |
| circRNA circ_0026344 | Down-regulated       | CCL20 and CXCL8 co-stimulation                            | Restrain metastasis                           | Colorectal cancer                              | [101]     |
Besides, a recent study unravels that IL-6 could interfere with circRNA biogenesis. DEx-H Box Helicase 9 (DHX9) is an RBP which is verified to disrupt the circularization of circRNA cGGNBP2 by binding to its flanking inverted complementary sequences in intrahepatic cholangiocarcinoma (ICC). However, upon IL-6 treatment, DHX9 is markedly downregulated, thus attenuating its inhibitory effects on the biogenesis of cGGNBP2. The upregulated cGGNBP2 thereby promotes ICC cell proliferation and metastasis in vitro and in vivo by encoding a novel protein named cGGNBP2-184aa. Notably, cGGNBP2 also participates in a positive feedback loop involving IL-6, cGGNBP2-184aa, and STAT3, which sustains the constitutive activation of inflammatory IL-6/STAT3 signaling and accelerates ICC progression [81].

In addition to IL-6, Zheng et al. demonstrated that IL-8 secreted by M2 macrophages triggered the transcriptional activation of MALAT1 via STAT3 pathway in inflamed prostate cancer cells, while upregulated MALAT1 expression then promoted cellular proliferation and metastasis [82]. The inflammatory cytokine IL-1β has been found to modulate the expression of various miRNAs linking inflammation to cancer progression. For instance, the elevated expression of miR-181a in colon cancer and miR-425 in gastric cancer are both attributed to activated IL-1β/NF-κB signaling axis, and they are both able to promote cancer cell proliferation by
repressing tumor suppressor PTEN, which is frequently mutated in many human malignancies [86, 87]. However, further investigations are warranted to determine whether other interleukins (e.g., IL-2, IL-10, IL-11, IL-12, IL-17, IL-23) can orchestrate ncRNA expression.

**Tumor necrosis factors**

As a kind of multifunctional pro-inflammatory cytokine in TME, TNFs are capable of activating multiple inflammatory signaling cascades which consequently drive differential protein-coding and noncoding transcriptome profiles [103]. As an example, Liu and colleagues identified a lncRNA NKILA which showed dramatic upregulation upon TNF-α treatment in breast cancer cells and suppressed breast cancer metastasis. Initially, the authors conducted RNA-microarray (GEO accession number: GSE57539) to screen differentially expressed lncRNAs in breast cancer cells upon treatment with various inflammatory mediators, and identified NKILA as a representative due to its significant stimulation upon all kinds of inflammatory stimuli (Additional file 1: Figure S1c). Further mechanistic study demonstrated that TNF-α upregulated NKILA at transcriptional level via NF-κB signaling, specifically with the NF-κB complex binding upregulated NKILA at transcriptional level via NF-κB

**Interferons**

IFNs are pleiotropic cytokines that exert vital roles in activating immune responses in malignant cancer [104]. Existing literature has documented that Type I IFN induces miR-21 expression via both JAK/STAT3 and NF-κB signaling pathways [74]. Huang et al. comprehensively analyze IFN-regulated lncRNAs via performing RNA-seq of IFN-β-treated and control esophageal squamous cell carcinoma (ESCC) cells (GEO accession number: GSE124514), and identifies a novel IFN-inducible nuclear lncRNA IRF1-AS in ESCC (Additional file 1: Figure S1d). IFNs elevate IRF1-AS expression via the classical JAK/STAT signaling pathway. Functionally, IRF1-AS functions as a tumor suppressor which restrains ESCC proliferation and induces apoptosis in vitro and in vivo. Meanwhile, an in-depth mechanistic study reveals that IRF1-AS enhances the transcriptional activation of IRF1 through interacting with ILF3 and DHX9. As an important transcription factor, IRF1 then conversely binds to the IRF1-AS promoter and activates IRF1-AS transcriptional activity, while also elevating the production of IFNs and transcription of many IFN-stimulated genes, ultimately forming a positive regulatory loop that stimulates the IFN response and IFN pathway gene expression to elicit a tumor-suppressive role in ESCC [96].

Meanwhile, Huang et al. also identify another IFNs-inducible lncRNA GAS5 which shows similar modes of action as IRF1-AS. GAS5 interacts with the IFN signaling and also forms a positive regulatory circuit that displays antitumor effects [97].

**Chemokines**

Chemokines are small, secreted proteins that are well-known for their roles in mediating immune cell trafficking and stimulating cancer growth and metastasis [105]. CC-chemokine ligand 21 (CCL21), which was remarkably upregulated in both gastric cancer and leukemia, induces the overexpression of oncogenic lncRNA MALAT1 which activates the mTOR signaling pathway, thereby expediting the EMT process to enhance the migratory and invasive capabilities of gastric cancer cells and cutaneous lymphoma cells [83, 84]. In addition, CXC-chemokine ligand 14 (CXCL14), which is secreted by CAFs, stimulates the expression of LINC00092 in ovarian cancer cells. According to lncRNA microarray analysis (GEO accession number: GSE82059), LINC00092 is among the top five most upregulated lncRNAs treated with recombinant CXCL14 protein in ovarian cancer cells (Additional file 1: Figure S1e). As for the functional mechanism, LINC00092 binds to the EMT process, migratory and invasive capacity of cervical cancer cells [95].
fructose-2,6-bisphosphatase PFKFB2, a glycolytic enzyme, to alter glycolysis of ovarian cancer cells and maintain the CAFs-like phenotype of fibroblasts in TME, subsequently accelerating metastasis. This study highlights a reciprocal feedback loop mediated by LINC00092 between CXCL14-positive CAFs and ovarian cancer cells that is crucial for promoting the metastatic behavior of ovarian cancer [98]. Additionally, in the inflammation-driven colorectal cancer (CRC) cells, the activated CXCL12/CXCR4 axis results in a robust increase in IncRNA XIST, which attenuates repression of RhoA signaling by sponging miR-133a-3p, thus enhancing the cytoskeletal reorganization and invasive capacities of CRC cells [99]. Moreover, CCL18 is shown to induce the expression of IncRNA HOTAIR in ESCC. HOTAIR functions as a miR-130a-5p sponge to positively regulate ZEB1, leading to the invasiveness of ESCCC cancer cells [94]. Meanwhile, CCL18 also enhances the proliferation and metastatic potential of oral squamous cell carcinoma cancer cells via LINC00319/miR-199a-5p/Fzd4 signaling pathway [100]. Aside from IncRNAs, circ_0026344 is downregulated by CCL20 and CXCL8 synergized treatment in CRC cell lines. Circ_0026344 knockdown alleviates the inhibitory effects on CRC cell migration and invasion through restoring miR-183-dependent Wnt/β-catenin signaling pathway [101]. To sum up, similar to cytokines, chemokines, which were previously illustrated to modulate protein-coding gene expression via STAT or NF-κB pathway [103, 106], are also able to regulate the expression of numerous ncRNAs. However, the precise molecular mechanism regarding ncRNA regulation by chemokines was not clarified in the above studies.

In spite of the aforementioned inflammatory factors, a plethora of other inflammatory mediators also participates in tumor-related inflammation. Nevertheless, whether and how these inflammatory factors manipulate ncRNA expression has not been thoroughly elucidated.

**NcRNAs regulated by nutrient deprivation**

Nutrient deprivation represents one of the main features of TME. Cancer cells generally consume a diversity of nutrients in amounts that substantially exceed those of normal cells, especially glucose and glutamine which serve as two major nutrient sources for cancer cells. To survive in the nutritionally restricted TME, various nutrient-sensing mechanisms and metabolic machineries are observed to orchestrate the metabolic reprogramming of cancer cells [107–110]. Notably, ncRNAs emerge as key players in these metabolic adaptive responses. Accumulating evidence has illustrated that an array of ncRNAs are dysregulated under nutrient-limiting conditions. These ncRNAs exert profound roles in metabolic alterations and malignant transformation of cancer cells. Previous literature primarily focuses on identifying the biological roles and functional mechanisms of ncRNAs during cancer metabolism, which have been systematically reviewed elsewhere [111–114]. However, the information about the regulatory pattern of ncRNAs has comparatively lagged behind, in contrast to the wealth of publications concerning their biological functions. Therefore, in this section, we provide current knowledge on the underlying mechanisms by which ncRNAs are regulated under different kinds of nutrient stress (Table 3, Fig. 3).

**Glucose deprivation**

Glucose, as a central bioenergetic source, is widely consumed by cancer cells at high levels to fuel their growth. Increased glucose catabolism depletes local supply and results in glucose deprivation [132, 133]. Glucose availability modulates several signaling pathways and activity of numerous transcription factors, thus altering the transcriptional program of certain sets of noncoding genes. As an example, an increase in cellular AMP/ATP ratio caused by glucose deprivation activates the adenosine monophosphate-activated protein kinase (AMPK), which serves as a principal sensor of cellular energy status [134, 135]. The AMPK signaling pathway has been demonstrated to provide a link between nutrient-depleted signals and ncRNA regulation. One of such cases in GBM is that AMPK activation upon glucose starvation results in inactivation of transcription factor OCT1 via direct phosphorylation at serine 335, which subsequently disrupts the transcription of miR-451. Inhibition of miR-451 then conversely sustains activation of AMPK signaling and a robust response to low glucose availability in TME. This study highlights a reciprocal negative feedback loop mechanism that render GBM cells adaptive to nutrient stress [115]. In addition, under conditions of glucose depletion, activated LKB1/AMPK pathway stimulates the expression of IncRNA MITA1. Mechanistically, AMPK mediates the increased binding of DNMT3B to the CpG island within the second intron of the MITA1 locus. Overexpression of MITA1 further promotes the EMT transition of HCC cells in vitro and HCC metastasis in vivo by upregulating Slug transcription [116]. Another IncRNA NBR2 is also induced under glucose-deprived conditions via the LKB1/AMPK pathway. At the beginning of this study, to identify nutrient-stress-induced IncRNAs, the authors perform an RNA-seq analysis (GEO accession number: GSE77415) to establish IncRNA expression profile in kidney cancer cells cultured in glucose-containing or glucose-free medium. Subsequent computational analysis discovers NBR2 to be markedly induced by glucose starvation (Additional file 1: Figure S1f). Induced IncRNA NBR2, in turn, interacts with AMPK and potentiates AMPK kinase activation, forming
an NBR2-AMPK feedforward loop that contributes to tumor growth. NBR2 functions as a tumor suppressor in human breast and renal cancer. Depletion of NBR2 leads to unchecked cell cycling, altered apoptosis response, and enhanced tumor development [117].

Moreover, transcription factor p53 has been well-documented to be upregulated and modulate gene expression under diverse intrinsic and extrinsic stimuli including nutrient scarcity [136]. Various lncRNAs are direct transcriptional targets of activated p53 under glucose-deprived conditions. For example, Khan and colleagues observed that in the presence of low glucose availability, p53 elevation transcriptionally upregulates the lncRNA TRINGS in multiple cancer cell lines. TRINGS physically interacts with STRAP and inhibits STRAP-GSK3B-NF-κB necrotic signaling to protect cancer cells against necrosis. It is interesting to note that TRINGS only specifically responds to glucose starvation, while its expression is not affected by other nutritional deficiencies such as serum, serine, or glutamine deprivation [118].

In addition, the GCN2/ATF4 signaling axis is recently observed to mediate linc01564 induction in HCC cells under low-glucose conditions. Linc01564 increases PHGDH expression through sequestering miR-107/103a-3p, hence activating serine synthesis pathway to support

Table 3 Nutrient deprivation-regulated ncRNAs and their roles during cancer progression

| NcRNAs        | Expression upon nutrient deprivation | Regulatory mechanisms | Functions                                                                 | Cancer types                      | References |
|---------------|--------------------------------------|-----------------------|---------------------------------------------------------------------------|----------------------------------|------------|
| miRNA-451     | Down-regulated under glucose deprivation | AMPK/OCT1             | Promote adaptive response                                                  | Glioblastoma                     | [115]      |
| IncRNA MITA1  | Up-regulated under glucose starvation | AMPK-mediated DNA methylation | Enhance EMT transition                                                      | Hepatocellular carcinoma         | [116]      |
| IncRNA NBR2   | Up-regulated under glucose starvation | LKB1/AMPK             | Regulate proliferation, apoptosis, and autophagy                          | Breast cancer, renal cancer      | [117]      |
| IncRNA TRINGS | Up-regulated under glucose starvation | p53                   | Regulate cancer cell necrosis                                              | Multiple cancers                  | [118]      |
| lncRNA 01,564 | Up-regulated under glucose deprivation | GCN2/ATF4 axis        | Mediate metabolism remodeling                                              | Hepatocellular carcinoma         | [119]      |
| IncRNA FILNC1 | Up-regulated under glucose deprivation | FOXO                  | Regulate energy metabolism                                                 | Renal cancer                      | [120]      |
| IncRNA MACC1-AS1 | Up-regulated under glucose deprivation | N.A                  | Promote cancer cell metabolic plasticity and survival                     | Gastric cancer                    | [121]      |
| IncRNA LOC730101 | Up-regulated under glucose deprivation | N.A                  | Regulate cancer cell survival, viability, apoptosis                       | Osteosarcoma                      | [122]      |
| IncRNA GLCC1  | Up-regulated under glucose deprivation | N.A                  | Enhance glycolysis, support cell survival, and proliferation              | Colorectal cancer                 | [123]      |
| IncRNA HAND2-AS1 | Up-regulated under glucose deprivation | N.A                  | Repress glycolysis                                                         | Osteosarcoma                      | [124]      |
| IncRNA HOXC-AS3 | Up-regulated under glucose deprivation | N.A                  | Trigger metabolic reprogramming                                             | Breast cancer                     | [125]      |
| miRNA-135     | Up-regulated under glucose deprivation | p53                   | Suppress glycolysis and promote tumor growth                              | Pancreatic ductal adenocarcinoma  | [126]      |
| IncRNA GLS-AS | Down-regulated under glucose/glutamine deprivation | c-Myc                | Facilitate cancer cell proliferation and invasion                         | Pancreatic cancer                 | [127]      |
| IncRNA GIRGL  | Up-regulated under glutamine deprivation | c-JUN and HuR         | Support cancer cell survival                                               | Colon cancer                      | [128]      |
| IncRNA BC200  | Down-regulated under serum deprivation | c-Myc                | Reduce cancer cell viability                                               | Breast cancer, lung cancer        | [129]      |
| circRNA ACC1  | Up-regulated under serum deprivation | c-JUN                | Support tumor growth                                                        | Colorectal cancer                  | [130]      |
| circRNA Hsa_circ_0062682 | Up-regulated under serum and serine deprivation | N.A                | Promote serine synthesis and tumor growth                                 | Colorectal cancer                  | [131]      |
HCC cell survival and proliferation in vitro and xeno-graft tumor growth in vivo [119]. Besides, another lncRNA FILNC1 was induced by activated transcription factor FOXO in renal cancer cells under glucose deficiency. Elevated FILNC1 sequesters AUF1 from binding c-Myc mRNA, leading to downregulation of c-Myc protein which subsequently represses energy metabolism and impedes renal tumor development [120]. Despite these above-mentioned ncRNAs, many other ncRNAs were also revealed to be upregulated by glucose deprivation, including lncRNA MACC1-AS1 [121], lncRNA LOC730101 [122], lncRNA GLCC1 [123], lncRNA HAND2-AS1 [124], and lncRNA HOXC-AS3 [125], which are implicated in cellular processes such as metabolic reprogramming, survival, apoptosis, and proliferation in many malignancies, whereas the exact molecular mechanisms underpinning their increased expression remain elusive.

**Other nutrient deprivation**

Similar to glucose, glutamine is another essential nutrient in cancer metabolism. Due to surged glutamine usage and inadequacies of tumor vascular supply, aggravated glutamine deprivation occurs in the tumor core regions [110]. NcRNAs are shown to be dysregulated under low-glutamine conditions through various mechanisms. For instance, miR-135 accumulates specifically as a response to glutamine deprivation in pancreatic ductal adenocarcinoma (PDAC). Mechanistically, glutamine depletion induces ROS which activates mutp53 and potentiates the binding of mutp53 to miR-135 promoter region, thereby inducing miR-135 transactivation. Functionally, miR-135 targets PFK1, resulting in suppressed glycolysis and enhanced cancer growth [126]. Alternatively, in pancreatic cancer cells, lncRNA GLS-AS is transcriptionally inhibited by induced c-Myc upon glutamine depletion. Downregulated GLS-AS mediates the reciprocal feedback loop of glutaminase and Myc, hence supporting pancreatic cancer cell survival and dissemination during nutrient stress. Notably, results proved that GLS-AS repression is only observed during glutamine and glucose starvation [127]. Moreover, since it has been previously established that glutamine insufficiency invokes stress-activated JNK/c-JUN signaling [137, 138], a study recently characterizes a lncRNA named GIRGL which is transactivated by c-JUN in colon cancer cells deprived of glutamine. In addition, beyond transcription control, it is also observed that GIRGL turnover can be restrained via a human antigen R (HuR)/Ago2-mediated mechanism. RBP HuR, which is known for destabilizing mRNA
and IncRNA transcript or modulating mRNA translation [139, 140], binds to GIRGL transcript and accelerates its degradation through recruitment of RISC. However, this negative regulation of GIRGL by HuR appears to be diminished in the absence of glutamine. Collectively, the dual mechanisms establish a feedback loop serving to balance cellular GIRGL levels in response to fluctuating glutamine concentration. Upregulation of GIRGL under glutamine-deficient conditions drives the formation of GIRGL/CAPRIN1/glutaminase-1 mRNA complex and promotes phase separation of this complex into stress granules, resulting in the translational suppression of glutaminase-1 mRNA which eventually supports cancer cell survival upon prolonged glutamine deprivation stress [128]. Despite glutamine, the levels of other amino acids, including serine, asparagine, arginine and aspartic acid are also significantly decreased in tumor core region [141], whereas much less is known with respect to whether these types of nutrient limitations affect ncRNAs or not.

Besides glucose and glutamine deprivation, a limited supply of serum components also frequently occurs in TME, which is referred to as serum deprivation [142]. A study reports that IncRNA BC200 expression is inactivated via c-Myc upon serum deprivation. Knockdown of BC200 reduces cell survival and proliferation in a spectrum of cancer cell lines [129]. Similarly, serum deprivation upregulates circACC1 in colorectal cancer cells by transcription factor c-JUN. CircACC1 contributes to the metabolic switch in response to serum deprivation. Mechanistically, circACC1 assembles and stabilizes the AMPK complex, ultimately increasing both glycolysis and fatty acid β-oxidation that further support colorectal cancer development [130]. Lastly, it is reported that Hsa_circ_0062682, a serum and serine starvation-induced circRNA, promotes serine metabolism and tumor growth via miR-940/PHGDH axis in colorectal cancer [131].

As discussed above, nutrient deprivation in TME could contribute to aberrant expression of ncRNAs in cancer cells through a series of transcriptional/post-transcriptional perturbations and epigenetic alterations. However, further studies are required to unravel other direct or indirect regulatory mechanisms. For instance, investigations are required to identify more nutrient-stress-responsive RBPs that could elicit post-transcriptional regulation on ncRNAs. Furthermore, since both glucose and amino acid depletion were reported to induce mTOR-MDM2-Drosha axis that broadly orchestrated miRNA biogenesis in lung cancer cells [143], we propose that nutrient deficiency might also affect IncRNA and circRNA biogenesis via similar pathways. Moreover, in response to low nutrient availability, a variety of activated metabolic enzymes and secreted metabolites can impact chromatin structure and transcription directly or indirectly by modulating histone-modifying enzymes, chromatin-remodeling complexes, and transcription regulators, displaying potential impact on ncRNA expression. Besides, the interplays between deregulated metabolic activities and various kinds of covalent modifications have been validated to exert regulation on gene expression in tumor development, which also implies potential regulatory effects on expression of ncRNAs [144].

### NcRNAs regulated by other tumor environmental stresses

As tumor develops, in spite of these above-described stresses, endoplasmic reticulum (ER) stress, oxidative stress, acidosis also occur prevalently in TME and display modulatory effects on ncRNA expression (Table 4). Adverse external and internal factors result in accumulation of unfolded or misfolded proteins in the endoplasmic reticulum in cancer cells, which triggers a stressful condition termed ER stress and elicits the unfolded protein response (UPR) to restore intracellular homeostasis. To adapt to unfavorable conditions, some transcription factors downstream of UPR sensors strictly coordinate transcriptional activities to ensure gene expression. Increasing evidence indicates that ER stress affects the expression level of miRNAs and IncRNAs,

| NcRNAs | Expression upon stress conditions | Regulatory mechanisms | Functions | Cancer types | References |
|--------|----------------------------------|-----------------------|-----------|--------------|------------|
| IncRNA GOLGA2P10 | Up-regulated under ER stress | PERK/ATF4/CHOP pathway | Regulate cancer cell apoptosis | Hepatocellular carcinoma | [145] |
| IncRNA MALAT1 | Up-regulated under ER stress | IRE1/XBP1 and PERK/eIF2α/ATF4 pathways | Promote cancer metastasis | Colorectal cancer | [146] |
| miR-23a-3p | Up-regulated under ER stress | N.A | Promote immune escape | Hepatocellular carcinoma | [147] |
| IncRNA HISLA | Up-regulated under acidosis | ERK/ELK1 signaling | Promote aerobic glycolysis and chemo resistance | Breast cancer | [148] |
whereas there are barely any reports concerning circRNAs [14]. For example, an ER-stress-responsive C/EBP-homologous protein (CHOP) is a transcription factor that regulates many genes involved in ER-stress-induced apoptosis. CHOP is reported to transactivate IncRNA GOLGA2P10 by directly binding to its promoter region. Overexpression of GOLGA2P10 enables HCC cells to evade ER-stress-triggered apoptosis and survive under stress conditions by increasing BCL-xL protein level and promoting BAD phosphorylation [145]. Another report from Jiang et al. reported that upon ER stress, IncRNA MALAT1 expression was increased via activation of IRE1/XBP1 and PERK/eIF2α/ATF4 signaling pathways. Augmented IncRNA MALAT1 then promotes colorectal cancer metastasis [146]. Interestingly, crosstalk between ER stress and ncRNAs has been identified during tumorigenesis and progression. Many transcription factors downstream of ER-stress-triggered UPR signaling pathway bind to the promoter regions of ncRNAs to activate their transcription, and certain ncRNAs can reciprocally modulate the UPR signaling pathway [14]. One of such example is the aforementioned IncRNA GOLGA2P10, which forms a feedback loop with the CHOP signaling to prevent tumor cells against CHOP-induced apoptosis [145]. Particularly, ER stress is reported to stimulate exosomal secretion of ncRNAs, which promotes the dynamic intercellular communications between various cell types in TME. As an example, Liu et al. reveal that ER stress contributes to exosome secretion and elevated exosomal miR-23a-3p level in HCC cells. The miR-23a-3p-enriched exosomes can be taken up by infiltrated macrophages in TME, which then leads to enhancement of PD-L1 expression in macrophages and inhibition of T cell function, ultimately promoting HCC immune escape [147].

Oxidative stress results from the imbalance between the production of oxidative agents and antioxidants. Excessive free radicals such as reactive oxygen species (ROS) or reactive nitrogen species (RNS) often accumulate in cancer, leading to oxidative stress conditions [6]. Substantial miRNAs are reported to be regulated by oxidative stress via diverse mechanisms [13], whereas there is very limited literature discussing the exact mechanisms by which oxidative stress modulates IncRNA and circRNA expression. Considering that the increase of ROS and RNS can activate multiple signaling pathways such as MAPK, NF-κB, STAT3, PPARγ, or NRF2 to regulate the redox status of cells [6], these signaling pathways are also likely to exert regulatory effects on ncRNAs. Meanwhile, elevated ROS and RNS have been well-identified to trigger epigenetic reprogramming by modulating different chromatin-modifying enzymes [149–151], representing another potential regulatory mechanism for ncRNAs upon oxidative stress.

As a result of aerobic glycolysis, glucose in cancer cells is mainly processed into lactate, forming an acidic TME. Acidic TME strongly influences tumorigenesis [152]. A recent study by Chen et al. showed that lactate in the TME upregulated IncRNA HISLA in TAMs. Further mechanistic study uncovered that lactate activated ERK/ELK1 signaling in TAMs, which was proven to be responsible for the upregulation of HISLA. TAMs subsequently released extracellular vesicles containing HISLA to promote aerobic glycolysis and chemoresistance of breast cancer cells [148].

Overall, further investigations are warranted to elucidate the comprehensive regulatory networks of ncRNAs under various kinds of TME stress.

Conclusions and perspectives
Over the course of tumor development, tumor cells are subjected to various adverse factors in TME: hypoxia, inflammation, nutrient deprivation, oxidative stress, acidosis, ER stress, and physical pressure. Under these TME stress conditions, a series of genomic alterations and adaptive responses are activated in tumor cells to support their continued growth, survival, and metastasis [2–6]. Given that TME plays a fundamental role during multiple stages of cancer development, future research will be aimed at deciphering the modes of action and in-depth molecular mechanisms of TME. Currently, as one of the most fast-emerging fields of research, ncRNAs have provided novel insights into the complexity of regulation under multiple stresses. Owing to its flexible structure for interaction and quick biogenesis nature, ncRNAs could be uniquely suited to provide a rapid, precise, and reversible response to major intrinsic changes and adverse environmental challenges. An increasing body of evidence has proved that various stresses in TME dramatically alter the expression levels of ncRNAs. These abnormally expressed ncRNAs participate in many biological processes of tumorigenesis.

Previous studies primarily centered around elucidating the biological functions and downstream effects of dysregulated ncRNAs in multiple cancer types, which have been extensively reviewed elsewhere [7, 8, 68, 153, 154]. However, there is still a lack of mechanistic studies to unravel how ncRNA levels are abnormally altered in cancer. Since ncRNA expression has been widely observed to be profoundly affected by TME stress conditions, the molecular mechanisms whereby TME stresses regulate ncRNA expression remain to be further clarified. As discussed throughout this review, we elaborate on the signal transduction pathways and epigenetic pathways through which HIFs, inflammatory factors, and nutrient deprivation in TME regulate ncRNAs, and highlight the multifaceted roles of TME stress-related ncRNAs in tumors.
The mechanistic dissection of various TME stresses and their regulatory patterns on ncRNAs has advanced our understanding of tumor formation and progression. Nevertheless, more detailed mechanistic studies are still required, particularly in terms of other stress conditions like acidosis, oxidative stress, and ER stress. In addition to the well-appreciated transcriptional regulation and epigenetic modification, post-transcriptional regulation also profoundly impacts ncRNA biogenesis, stability, and biological functions. However, whether TME stresses affect post-transcriptional regulation remains largely elusive. Further, diverse post-translational modifications of proteins like histone, transcription factors, chromatin-modifying enzymes, and RNA polymerase II are known to be regulated by various stress stimuli [144, 155, 156], while their subsequent influences on ncRNA expression yet remain obscure. On the other hand, the current knowledge regarding the regulatory effects of TME stress principally focuses on miRNAs and lncRNAs, whereas emerging ncRNA species like circRNAs and piRNAs await investigation. Moreover, another important question is raised by the close integration of various types of TME stresses. Various stresses tend to coexist in tumor tissues. For instance, the occurrence of hypoxia often results in metabolic stress and ER stress [14, 16]. A hypoxic state and abnormal metabolic state induce the production of ROS, which aggravates oxidative stress [6]. This adds complexity and heterogeneity to the regulatory networks in vivo. Accordingly, it would be crucial to investigate how these stresses interact with each other and cooperate to influence ncRNA expression and cancer development. Additionally, it is interesting to further study the role (feedforward loop) of different ncRNAs in aggravating or inhibiting the TME stress. Lastly, to our best knowledge, the existing literature mainly focuses on discussing the roles of TME stress-responsive ncRNAs in regulating the cellular behavior of neoplastic cells, meanwhile, it is also fascinating to discuss their impact on different stromal cells, including endothelial cells, CAFs, as well as immune cells which are indispensable components of the TME, since this regulatory network may also indirectly contribute to tumor pathogenesis and progression.

Given the prominent pathological roles played by ncRNAs in cancer, novel classes of RNA-based therapeutics have shown potential to be clinically beneficial in the treatment of many diseases including cancer. For example, the antisense oligonucleotide and small interfering RNAs are employed to deplete lncRNA directly. Splice-switching oligonucleotide can be utilized to excise lncRNA exon that encodes necessary functional domains. Steric blocking oligonucleotides may interfere with the interaction of lncRNAs with their binding partners. These RNA-based methods present possibilities to modulate the functions of lncRNAs in diverse ways. Some of these drugs have been developed and are in clinical trials or in some cases approved for clinical use [157]. Furthermore, in light of our deeper understanding of how TME stress regulates numerous ncRNAs in the process of tumorigenesis and cancer progression, we propose that interfering with the regulatory network between TME stresses and ncRNAs, specifically by targeting key transcription factors, major signal transduction pathways, epigenetic pathways, or post-transcriptional modification could also be potentially feasible for cancer treatment. Finally, it is important to highlight that targeting different ncRNAs in combination with other drugs or inhibitors which can target TME stress shows great therapeutic benefit in cancer treatment. Particularly due to the feedback loops that frequently exist between TME-stress-regulated signaling pathways and ncRNAs, the combined therapy may display synergistic effects in promoting or inhibiting the regulatory function of TME stress on tumor development. In the study of Xiang et al., tumor suppressor miR-146b repletion and JAK inhibition exert greater inhibitory effects on breast cancer cell viability than either agent alone [76]. Another study of Li et al. reveals that interventions targeting circRNA cGGNBP2 provide potential auxiliary benefits for IL-6/STAT3-based treatments in ICC [81]. Currently, many drugs or inhibitors that can target TME-stress-regulated signaling pathways have been developed, such as acriflavine and belzutifan which target HIF [158, 159], siltuximab which targets IL-6 [160]. However, there are very limited investigations on the combined therapy of these inhibitors and ncRNAs, which deserves to be further studied. It is hopeful that over the next decades, as the elaborate regulatory networks between TME and ncRNAs in cancer pathogenesis are described in greater detail and clarity, it may provide promising biomarker and therapeutic targets for cancer therapy.

Abbreviations

AMPK: Adenosine monophosphate-activated protein kinase; AS: Alternative splicing; CAFs: Cancer-associated fibroblasts; CCL21: CC-chemokine ligand 21; CHIP: Chromatin immunoprecipitation; C/EBP: CCAAT/enhancer binding protein; CRC: Colorectal cancer; CXCL14: CXC-chemokine ligand 14; DNMT1: DNA methyltransferase 1; EMSA: Electrophoretic mobility shift assay; ER: Endoplasmic reticulum; EsCC: Esophageal squamous cell carcinoma; GBM: Glioblastoma; HCC: Hepatocellular carcinoma; HDACs: Histone deacetylases; HIFs: Hypoxia-inducible factors; HREs: Hypoxia response elements; HSPCs: Hematopoietic stem and progenitor cells; HuR: Human antigen R; ICC: Intrahepatic cholangiocarcinoma; IFNs: Interferons; ILs: Interleukins; JAK/STAT: Janus kinase-signal transducer and activator of transcription; KDMs: Histone lysine demethylases; LncRNAs: Long ncRNAs; MDSCs: Myeloid-derived suppressor cells; miRNAs: MicroRNAs; N.A.: Not available; ncRNAs: Noncoding RNAs; NF-κB: Nuclear Factor-κB; OSCC: Oral squamous cell carcinoma; PDAC: Pancreatic ductal adenocarcinoma; piRNAs: PIWI-interacting RNAs; PTEN: Phosphatase and tensin homolog; RBPs: RNA-binding proteins; RCC: Renal cell carcinoma; RNS: Reactive nitrogen species; ROS: Reactive oxygen species; siRNAs: Small
interfering RNAs; snRNAs: Small ncRNAs; snoRNAs: Small nuclear RNAs; snRNA: Small nuclear RNAs; SP1: Specific protein 1; TAMs: Tumor-associated macrophages; TET2: Ten-eleven-translocation 2; TET3: Ten-eleven-translocation 3; TME: Tumor microenvironment; TNFs: Tumor necrosis factors; tsRNAs: Transfer RNA-derived small RNAs; UPR: Unfolded protein response; VHL: Von Hippel-Lindau protein.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13046-022-02433-y.

Additional file 1: Figure S1. Heatmaps showing differentially expressed ncRNAs in response to several TME stress. a Heatmap showing most upregulated and downregulated lncRNAs in OSCC cells cultured under normoxic and hypoxic conditions [30]. b Differentially expressed IncRNAs in normoxic and hypoxic MCF10A cells [56]. c Most upregulated and downregulated IncRNAs (more than 10-fold) by various inflammatory stimuli (LPS, IL-1β, TNF-α) [86]. d Expression profiles of differentially regulated IncRNAs (over 2-fold change in expression) in three ESCC cell lines (KYE530, KYSE180, KYSE450) treated with PBS or IFN-β [95]. e Heatmap showing top upregulated or downregulated IncRNAs in A2780s ovarian cancer cell line treated with recombinant CXCL14 protein or control [100]. f Differentially expressed IncRNAs in 786-O cells with or without glucose treatment [121].

Acknowledgements

Not applicable.

Authors’ contributions

LY wrote the manuscript. LYH prepared the figures and tables. WZ, YKF, and ZY critically reviewed and edited the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by grants from the National Key Technologies R&D Program (2018YFC1106800), the Natural Science Foundation of China (82173124, 82173248, 82103533, 82002572, 82002967, 81972747, and 81872004), the fellowship of China National Postdoctoral Program for Innovative Talents (BX20200225, BX20200227), the China Postdoctoral Science Foundation (2021M692278, 2020M673231), the Science and Technology Support Program of Sichuan Province (2021YJ0436), the Postdoctoral Science Foundation of Sichuan University (2021SCU12007), the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYJC18008), and the Postdoctoral Science Foundation of West China Hospital (2020XHB075, 2020XHB007).

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Liver Surgery & Liver Transplantation, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, China.
2 Laboratory of Liver Surgery; West China Hospital, Sichuan University, Chengdu 610041, China.

Received: 17 February 2022 Accepted: 6 July 2022

Published online: 16 July 2022

References

1. Maman S, Witz IP. A history of exploring cancer in context. Nat Rev Cancer. 2018;18(6):359–76.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
3. Quall DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–37.
4. Lee P, Chandel NS, Simon MC. Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. Nat Rev Mol Cell Biol. 2020;21(5):268–83.
5. Oakes SA, Papa FR. The role of endoplasmic reticulum stress in human pathology. Annu Rev Pathol. 2015;10:173–94.
6. Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative Stress in Cancer. Cancer Cell. 2020;38(2):167–97.
7. Slack FJ, Chinnaiyan AM. The Role of Non-coding RNAs in Oncology. Cell. 2019;179(5):1033–55.
8. Wong CM, Tsang FH, Ng IO. Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat Rev Gastroenterol Hepatol. 2018;15(2):137–51.
9. Anastassiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18(1):15–18.
10. Choudhry H, Harris AL, McIntyre A. The tumour hypoxia induced non-coding transcriptome. Mol Aspects Med. 2016;47–48:35–53.
11. Rupainooore R, Calin GA, Lopez-Berestein G, Sood AK. miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discov. 2016;6(3):235–46.
12. Chakraborty C, Sharma AR, Sharma G, Lee SS. The Interplay among miRNAs, Major Cytokines, and Cancer-Related Inflammation. Mol Ther Nucleic Acids. 2020;20:6060–20.
13. Lu C, Zhou D, Wang Q, Liu W, Yu F, Wu F, et al. Crosstalk of MicroRNAs and Oxidative Stress in the Pathogenesis of Cancer. Oxid Med Cell Longev. 2020;2020:2415324.
14. Zhao T, Du J, Zeng H. Interplay between endoplasmic reticulum stress and non-coding RNAs in cancer. J Hematol Oncol. 2020;13(1):163.
15. Choudhry H, Schödel J, Diokonomopoulos S, Camps C, Grampp S, Harris AL, et al. Extensive regulation of the non-coding transcriptome through hypoxia inducible factors and beyond. Nat Rev Mol Cell Biol. 2019;20(1):70–6.
16. Choudhry H, Harris AL. Advances in Hypoxia-Inducible Factor Biology. Cell Metab. 2018;27(2):281–98.
17. Deng K, Myers KA. The role of hypoxia-induced miR-210 in cancer progression. Int J Mol Sci. 2015;16(3):6533–72.
18. Devlin C, Greco S, Martelli F, Ivan M. miR-210: More than a silent player in hypoxia. IUBMB Life. 2011;63(2):94–100.
19. Nallamshetty S, Chan SY, Loscalzo J. Hypoxia: a master regulator of microRNA biogenesis and activity. Free Radic Biol Med. 2013;64:20–30.
20. Wu W, Hu Q, Nie E, Yu T, Wu Y, Zhi T, et al. Hypoxia induces H19 expression through direct and indirect HIF-1α activity, promoting oncogenic effects in glioblastoma. Sci Rep. 2017;7:45029.
21. Raveh E, Matouk IJ, Gilon M, Hochberg A. The H19 Long non-coding RNA in cancer initiation, progression and metastasis - a proposed unifying theory. Mol Cancer. 2015;14:1184.
22. Shih CH, Chuang LT, Tsai MH, Chen LH, Chuang EY, Lu TP, et al. Hypoxia-Induced MALAT1 Promotes the Proliferation and Migration of Breast Cancer Cells by Sponging MiR-3064-5p. Front Oncol. 2021;11:658151.
23. Ikeda S, Kitadate A, Abe F, Takahashi N, Tagawa H. Hypoxia-inducible KDM3A addiction in multiple myeloma. Blood Adv. 2018;2(4):323–34.
24. Stone JK, Kim JH, Yukadin L, Richard A, Giannini HK, Lim SS, et al. Hypoxia induces cancer cell-specific chromatin interactions and increases MALAT1 expression in breast cancer cells. J Biol Chem. 2019;294(29):11213–24.
25. Zhang P, Cao L, Zhou R, Yang X, Wu M. The IncRNA Neat1 promotes activation of inflammasomes in macrophages. Nat Commun. 2019;10(1):1495.
26. Choudhry H, Mole DR. Hypoxic regulation of the noncoding genome and NEAT1. Brief Funct Genomics. 2016;15(3):174–85.
27. Zhang Q, Cheng Q, Xia M, Huang X, He X, Liao J. Hypoxia-Induced IncRNA-NEAT1 Sustains the Growth of Hepatocellular Carcinoma via Regulation of miR-199a-3p/UCCQ. Front Oncol. 2020;10:1998.

28. Zhou C, Cheng Q, Xia M, Huang X, He X, Liao J. Hypoxia-Induced IncRNA-NEAT1 Sustains the Growth of Hepatocellular Carcinoma via Regulation of miR-199a-3p/UCCQ. Front Oncol. 2020;10:1998.

29. Bhan A, Deb P, Shihabeddin N, Ansari KI, Brotto M, Mandal SS. Histone methylation MLL1 coordinates with HIF and regulate IncRNA HOTAIR expression under hypoxia. Gene. 2017;629:16–28.

30. Hu M, Fu Q, Jing C, Zhang X, Qin T, Pan Y. LncRNA HOTAIR knockdown inhibits glycolysis by regulating miR-130a-3p/HIF1A in hepatocellular carcinoma under hypoxia. Biomed Pharmacother. 2020;125:109703.

31. Ren S, Liu J, Feng Y, Li Z, He L, Li L, et al. Knockdown of circDENND4C inhibits glycolysis and migration and invasion by up-regulating miR-200b/c in breast cancer under hypoxia. J Exp Clin Cancer Res. 2019;38(1):388.

32. Liang G, Liu Z, Tan L, Su AN, Jiang WG, Gong C. HIF1α-associated circDENND4C Promotes Proliferation of Breast Cancer Cells in Hypoxic Environment. Anticancer Res. 2017;37(8):4337–43.

33. Zhang ZJ, Zhang Y, Qin XJ, Wang YX, Fu J. Circular RNA circDENND4C facilitates proliferation, migration and glycolysis of colorectal cancer cells through miR-760/GLUT1 axis. Eur Rev Med Pharmacol Sci. 2020;24(5):2387–400.

34. Yang R, Chen H, Xing L, Wang B, Hu M, Ou X, et al. Hypoxia-induced circWS1 promotes breast cancer progression through destabilizing p53 by interacting with USP10. Mol Cancer. 2022;21(1):88.

35. Zhu G, Wang S, Chen J, Wang Z, Liang X, Wang X, et al. Long noncoding RNA HAS2-AS1 mediates hypoxia-induced invasiveness of oral squamous cell carcinoma. Mol Carcinog. 2017;56(10):9179–88.

36. Yang F, Zhang H, Mei Y, Wu M. Reciprocal regulation of HIF-1α and lncRNA-p21 modulates the Warburg effect. Mol Cell. 2014;53(1):88–100.

37. Liu J, Liu H, Zeng Q, Xu P, Liu M, Yang N. Circular RNA circ-MAT2B facilitates proliferation, migration and glycolysis of colorectal cancer cells through regulating the miR-515-5p/HIF-1α axis. Cancer Cell Int. 2020;20:171.

38. Zeng Z, Zhao Y, Chen Q, Zhu S, Niu Y, Ye Z, et al. Hypoxic exosomal HIF-1α-stabilizing circZNF91 promotes chemoresistance of normoxic pancreatic cancer cells via enhancing glycolysis. Oncogene. 2021;40(36):5305–17.

39. Liang Y, Song X, Li Y, Chen B, Zhao W, Wang L, et al. LncRNA BCR12 promotes breast cancer progression by targeting miR-1303-3p/TP53 axis. Mol Cancer. 2020;19(1):85.

40. Niu Y, Bao L, Chen Y, Wang C, Luo M, Zhang B, et al. HIF-2-Induced Long Noncoding RNA RAB11B-AS1 Promotes Hypoxia-Mediated Angiogenesis and Breast Cancer Metastasis. Cancer Res. 2020;80(5):964–75.

41. Yuan JH, Liu XN, Wang TT, Pan W, Tao QF, Zhou WP, et al. The MBNL3 antisense-oriented lncRNA controls WT1 expression in myeloid leukemia cells. PLoS ONE. 2015;10(3):e0119837.
75. Zhu H, Han C, Lu D, Wu T. miR-17–92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator. Am J Pathol. 2014;184(10):2628–39.

76. Xiang M, Binkbak NJ, Vafazadeh V, Walker SR, Yeh JE, Li S, et al. STAT1 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes. Sci Signal. 2014;7(310):ra11.

77. Wu J, Zhang J, Shen B, Yin K, Xu J, Gao W, et al. Long non-coding RNA GAS5 is induced by IL-6 signaling in STAT3-driven cancer phenotypes. Sci Signal. 2014;7(310):ra11.

78. Wu J, Zhang J, Shen B, Yin K, Xu J, Gao W, et al. Long non-coding RNA IncRNA IRF1-AS represses esophageal squamous cell carcinoma by promoting interferon response. Cancer Lett. 2019;459:86–99.

79. Huang J, Li J, Li Y, Lu Z, Che Y, Mao S, et al. Interferon-inducible IncRNA LINC00024A promotes esophageal squamous cell carcinoma growth by inhibiting apoptosis. Tumor Biol. 2018;39(3):1161–68.

80. Zhou L, Xiao Z, Liu X, Zhang J, et al. Long non-coding RNA LINCO0029acts in Cancer-Associated Fibroblasts to Drive Glycolysis and Progression of Ovarian Cancer. Cancer Res. 2017;77(16):3698–802.

81. Yu X, Wang D, Wang X, Sun S, Zhang Y, Wang S, et al. CCL21 promotes inflammation-driven colorectal cancer progression through activation of RhoA signaling by sponging miR-133a-3p. J Exp Clin Cancer Res. 2019;38(1):32.

82. Jiang X, Liu J, Li S, Jia B, Huang Z, Shen J, et al. CCL21-induced LINCO00319 promotes proliferation and metastasis in oral squamous cell carcinoma via the miR-199a-5p/FZD4 axis. Cell Death Dis. 2020;11(9):777.

83. Shen T, Cheng X, Liu X, Xiao C, Zhang H, Pan D, et al. Circ_0026344 reinforces metastasis of human colorectal cancer cells via miR-183. Artif Cells Nanomed Biotechnol. 2019;47(1):4038–45.

84. Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234–48.

85. Taniguchi K, Karim M. NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18(5):309–24.

86. Ishavishiv LB. IFNγ signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18(9):545–58.

87. Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer. Immunity. 2021;54(5):859–74.

88. Chen Y, Shao Z, Jiang E, Zhou X, Wang L, Wang H, et al. CCL21/CCL3 interaction promotes EMT and enhances the stemness of OSCC via a JAK2/STAT3 signaling pathway. J Cell Physiol. 2020;235(9):5995–6009.

89. Martinez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669–80.

90. Vander Heiden MG, DeBerardinis RJ. Understanding the Intersections between Metabolism and Cancer Biology. Cell. 2017;168(4):657–69.

91. Pavlova NN, Thompson CB. The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016;23(1):27–47.

92. Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: Still emerging. Cell Metab. 2022;34(3):355–77.

93. Yu T, Wang Y, Fan Y, Fang N, Wang T, Xu T, et al. CircRNAs in cancer metabolism: a review. J Hematol Oncol. 2019;12(1):90.

94. Kristensson LS, Jakobsen T, Hager H, Kjems J. The emerging roles of circRNAs in cancer and oncology. Nat Rev Oncol. 2021.

95. Lin W, Zhou Q, Wang CQ, Zhu L, Bi C, Zhang S, et al. LncRNAs regulate metabolism in cancer. Int J Biol Sci. 2020;16(7):1194–206.

96. Li T, Xiong JD, Han L, Zhang J, Lee SW, Wang W, et al. LncRNA NBR2 promotes colorectal cancer cell growth through miR-183. Cancer Cells Nanomed Biotechnol. 2019;47(1):4038–45.

97. Li T, Xiong JD, Han L, Zhang J, Lee SW, Wang W, et al. LncRNA NBR2 promotes colorectal cancer cell growth through miR-183. Cancer Cells Nanomed Biotechnol. 2019;47(1):4038–45.

98. Zhao L, Ji G, Le X, Wang C, et al. Circ_0004484 regulates cell proliferation and invasion in cervical cancer HeLa cells. Virus Res. 2020;281:197907.

99. Yu X, Wang D, Wang X, Sun S, Zhang Y, Wang S, et al. CXCL12/CXCR4 interaction promotes prostate tumorigenesis via STAT3/MALAT1 pathway. Int J Mol Sci. 2018;20(1).
122. Cheng G, Li B, Sun X, Cao Z, Zhang G, Zhao Z, et al. LncRNA LOC730101 promotes osteosarcoma cell survival under energy stress. Biochem Biophys Res Commun. 2018;496(1):1–6.

123. Tang J, Yan T, Bao Y, Shen C, Yu C, Zhu X, et al. LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc. Nat Commun. 2019;10(1):3499.

124. Kang Y, Zhu X, Xu Y, Tang Q, Huang Z, Zhao Z, et al. Energy stress-induced lncRNA HAND2-AS1 represses HIF1α-mediated energy metabolism and inhibits osteosarcoma progression. Am J Cancer Res. 2018;8(3):526–37.

125. Zhu W, Chen X, Guo X, Liu H, Ma R, Wang Y, et al. Low Glucose-Induced Overexpression of HOXC-AS3 Promotes Metabolic Reprogramming of Breast Cancer Cells. Cancer Res. 2022;82(5):805–18.

126. Yang Y, Ishak Gabra MB, Hanse EA, Lowman XH, Tran TQ, Li H, et al. Booy EP, McRae EK, Koul A, Lin F, McKenna SA. The long non-coding RNA BC200 (BCYRN1) is critical for cancer cell survival and proliferation. Mol Cancer. 2017;16(1):109.

127. Deng SJ, Chen HY, Zeng Z, Deng S, Zhu S, Ye Z, et al. Nutrient Stress-Dysregulated Antisense lnRNA GLS-AS Impairs GLS-Mediated Metabolism and Represses Pancreatic Cancer Progression. Cancer Res. 2019;79(7):1398–412.

128. Wang R, Cao L, Thorne RF, Zhang XD, Li J, Shao F, et al. LncRNA GIRC1 drives CRAP2R1-mediated phase separation to suppress glutaminase-1 translation under glutamine deprivation. Sci Adv. 2021;7(13).

129. Booy EP, McRae EK, Koul A, Lin F, McKenna SA. The long non-coding RNA BC200 (BCYRN1) is critical for cancer cell survival and proliferation. Mol Cancer. 2017;16(1):109.

130. Li Q, Wang Y, Wu S, Zhou D, Ding X, Shi R, et al. CircACC1 Regulates Assembly and Activation of AMPK Complex under Metabolic Stress. Cell Metab. 2019;30(1):157–73.e7.

131. Sun S, Li C, Cui K, Liu B, Zhou M, Cao Y, et al. Hsa_circ_0062682 Promotes Serine Metabolism and Tumor Growth in Colorectal Cancer by Regulating the miR-940/PGDHD Axis. Front Cell Dev Biol. 2021;9:770006.

132. Kanarek N, Petrova B, Sabatini DM. Dietary modifications for enhanced cancer therapy. Nature. 2020;579(7780):507–17.

133. Hay N. Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? Nat Rev Cancer. 2016;16(10):635–49.

134. Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018;19(2):121–35.

135. Steinberg GR, Carling D. AMP-activated protein kinase: the current landscape for drug development. Nat Rev Drug Discov. 2019;18(7):527–51.

136. Kastenhuber ER, Lowe SW. Putting p53 in Context. Cell. 2010;142(6):965–82.

137. Shanware NP, Bray K, Eng CH, Wang F, Follette M, Myers J, et al. Glutamine deprivation stimulates mTOR-JNK-dependent chemokine secretion. Nat Commun. 2014;5:4900.

138. Wu Q, Wu W, Fu B, Shi L, Wang X, Kuca K. JNK signaling in cancer cell survival. Med Res Rev. 2019;39(6):2082–104.

139. Abdelmohsen K, Gorospe M. Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip Rev RNA. 2010;1(2):214–9.

140. Yoon JH, Abdelmohsen K, Srikannt S, Yang X, Martindale JL, De S, et al. LincRNA-p21 suppresses target mRNA translation. Mol Cell. 2012;47(4):648–55.

141. Pan M, Reid NA, Lowman HM, Kulkarni RP, Tran TQ, Liu X, et al. Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation. Nat Cell Biol. 2016;18(10):1090–101.

142. Stavropoulos AV, MAVrofylli O, Salfig P, Efthimiopoulos S. Serum starvation induces BACE1 processing and secretion. J Alzheimer Res. 2017;14(6):45-6.

143. Ye P, Liu Y, Chen C, Tang F, Wu Q, Wang X, et al. An mTORC1-Mdm2-Drosha axis for miRNA biogenesis in response to glucose- and amino acid-deprivation. Mol Cell. 2015;57(4):708–20.

144. Li X, Egenvari G, Wang Y, Berger SL, Lu Z. Regulation of chromatin and gene expression by metabolic enzymes and metabolites. Nat Rev Mol Cell Biol. 2018;19(9):563–78.

145. Wu MZ, Fu T, Chen JX, Lin YY, Yang J, Zhaing SM. LncRNA GOLGA2P10 is induced by PERK/ATF4/CHOP signaling and protects tumor cells from ER stress-induced apoptosis by regulating Bcl-2 family members. Cell Death Dis. 2020;11(4):276.